FAK–paxillin signalling
Tendon-fibroblast experiments have examined focal-adhesion signalling, cell survival and migration.

Product images are for illustrative reference only. Final label layout and packaging details may vary by batch or production run. Product identity, strength and batch-specific documentation are provided separately and remain product-specific.
NOREXA PEPTIDES / RESEARCH MATERIAL
Lyophilized Peptide — Single vial
BPC-157 10 mg supplied exclusively as a laboratory research material. Available batch documentation is published only under its corresponding batch record.
Not for human or animal consumption.
Not intended to diagnose, treat, cure or prevent any disease.
RESEARCH & TECHNICAL OVERVIEW
BPC-157 is a synthetic 15-amino-acid research peptide. It is frequently described in the literature as a stable gastric pentadecapeptide, but the intact synthetic reagent should not be presented as a naturally occurring human peptide without direct evidence.
Published work is dominated by cell and animal models examining fibroblast migration, tendon-related signalling, angiogenesis and nitric-oxide-associated pathways. Robust human evidence remains limited.
For research use only. Not for human or veterinary use. Published findings describe the compound or related research systems; they are not claims about this NOREXA batch.
HANDLING INFORMATION
The cited reference does not establish an exact storage period for this product after reconstitution with bacteriostatic water.
MedChemExpress — BPC-157 technical record ↗SCIENTIFIC CONTEXT
Longer technical information is grouped for easier reading on desktop and mobile.
The sequence has been described as derived from a region associated with gastric proteins or gastric juice research. The laboratory compound itself is synthetic, and claims of an endogenous intact circulating BPC-157 molecule are not established by the references selected here.
Tendon-fibroblast experiments have examined focal-adhesion signalling, cell survival and migration.
Rat tendon-fibroblast studies reported changes in growth-hormone-receptor expression and downstream JAK2 responses.
Preclinical literature discusses vascular responses and interactions with nitric-oxide systems.
Lyophilized material may require preparation as a laboratory solution before use in an in-vitro assay. The solvent or buffer and working concentration should follow the applicable protocol and documentation for the exact molecular form.
This page intentionally provides no human dosing calculations, syringe-unit conversions, administration route or treatment schedule. Preparation conditions should be established and recorded by qualified laboratory personnel.
INDEPENDENT VERIFICATION
Purity alone is not enough. NOREXA distinguishes identity, purity and actual quantity, and publishes results only for the exact batch tested.
CURRENT BATCH / LOT
No identity, purity, quantity or batch number is shown as independently verified until exact product-and-lot evidence is available.
OPEN CENTRAL BATCH VERIFICATION →HISTORICAL BATCHES
No historical batch records are currently published for this product.
PRODUCT INFORMATION
Verified identity and catalogue information for this NOREXA research material. Unconfirmed fields are omitted.
Batch documentation and independent reports are shown only when published for the exact corresponding batch.
CHEMICAL IDENTITY REFERENCE ↗SELECTED SOURCES
Selected literature describes the compound and relevant research pathways; it does not constitute testing or endorsement of this NOREXA batch.
Journal of Applied Physiology · 2011
Molecules · 2014
Current Pharmaceutical Design · 2014
PRODUCT FAQ
The supplied research compound is synthetic. The selected literature describes its sequence in relation to gastric research, but does not establish the intact synthetic reagent as a naturally occurring human peptide.
Most published mechanistic evidence is in vitro or preclinical. That limitation is important and is shown directly on this page.
Selected studies examine focal-adhesion signalling, fibroblast migration, growth-hormone-receptor expression and vascular or nitric-oxide-related responses.
Not currently for this product. NOREXA will not display identity, purity or content as verified until an exact batch report is available.
SECTION 01 — STANDARDS
01 / 03Independent analytical results are presented as reported by the testing laboratory, without altering the laboratory’s findings.
02 / 03Each batch is assigned a record linking the product to its available technical and independent testing documentation.
03 / 03Available batch documentation is organized under the corresponding batch number for clear reference.
NOREXA PEPTIDES
RESEARCH ACCESS
Please confirm before entering the website.
RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY USE